Addressing ethnic disparity in asthma trials

Respirology

Volumn 19, Issue 6, 2014, Pages 775-776

  Radhakrishna, Naghmeh ^a   Hew, Mark ^a,b  

^a ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

asthma; ethnic disparity; Maori; subgroup analysis; symbicort maintenance and reliever therapy

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; SALBUTAMOL; BRONCHODILATING AGENT; BUDESONIDE; ETHANOLAMINE DERIVATIVE; FORMOTEROL;

AFRICAN AMERICAN; ASTHMA; CORTICOSTEROID THERAPY; DISEASE SEVERITY; EDITORIAL; ETHNIC GROUP; HEALTH DISPARITY; HOSPITALIZATION; HUMAN; MAORI (PEOPLE); METERED DOSE INHALER; NEW ZEALAND; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE; ETHNOLOGY; FEMALE; MALE; NEBULIZER;

ALBUTEROL; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; ETHANOLAMINES; FEMALE; HUMANS; MALE; NEBULIZERS AND VAPORIZERS;

EID: 84904570076     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12338     Document Type: Editorial

References (13)

1. Jenkins CR, Chang AB, Poulos LM, Marks GB,. Asthma in Indigenous Australians: so much yet to do for Indigenous lung health. Med. J. Aust. 2009; 190: 530-531.
2. Brown RW, Cappelletti CS,. Reaching beyond disparity: safely improving asthma control in the at-risk African-American population. J. Natl. Med. Assoc. 2013; 105: 138-149.
3. Holt S, Beasley R,. The burden of asthma in New Zealand. Report produced for the Asthma and Respiratory Foundation of New Zealand, 2001.
4. Steele AM, Meuret AE, Millard MW, Ritz T,. Discrepancies between lung function and asthma control: asthma perception and association with demographics and anxiety. Allergy Asthma Proc. 2012; 33: 500-507.
5. Federico MJ, Covar RA, Brown EE, Leung DY, Spahn JD,. Racial differences in T-lymphocyte response to glucocorticoids. Chest 2005; 127: 571-578.
6. Hew M, Bhavsar P, Torrego A, Meah S, Khorasani N, Barnes PJ, Adcock I, Chung KF,. Relative corticosteroid insensitivity of peripheral blood mononuclear cells in severe asthma. Am. J. Respir. Crit. Care Med. 2006; 174: 134-141.
7. Gould W, Peterson EL, Karungi G, Zoratti A, Gaggin J, Toma G, Yan S, Levin AM, Yang JJ, Wells K, et-al. Factors predicting inhaled corticosteroid responsiveness in African American patients with asthma. J. Allergy Clin. Immunol. 2010; 126: 1131-1138.
8. Wechsler ME, Castro M, Lehman E, Chinchilli VM, Sutherland ER, Denlinger L, Lazarus SC, Peters SP, Israel E, NHLBI Asthma Clinical Research Network. Impact of race on asthma treatment failures in the asthma clinical research network. Am. J. Respir. Crit. Care Med. 2011; 184: 1247-1253.
9. Wechsler ME, Kunselman SJ, Chinchilli VM, Bleecker E, Boushey HA, Calhoun WJ, Ameredes BT, Castro M, Craig TJ, Denlinger L, et-al. Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet 2009; 374: 1754-1764.
10. George S, Duran N, Norris K,. A systematic review of barriers and facilitators to minority research participation among African Americans, Latinos, Asian Americans, and Pacific Islanders. Am. J. Public Health 2014; 104: e16-31.
11. Rothwell PM,. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet 2005; 365: 176-186.
12. Pilcher J, Patel M, Smith A, Davies C, Pritchard A, Travers J, Black P, Weatherall M, Beasley R, Harwood M,. Combination budesonide/formoterol inhaler as maintenance and reliver therapy in Maori with asthma. Respirology 2014; 19: 842-851.
13. Patel M, Pilcher J, Pritchard A, Perrin K, Travers J, Shaw D, Holt S, Harwood M, Black P, Weatherall M, et-al. Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. Lancet Respir. Med. 2013; 1: 32-42.